ANXA2 and ovarian carcinoma: In 2013, Lokman et al. reported that anti-ANXA2 antibodies significantly blocked ovarian cancer cell invasion in a CAM model and cancer cell peritoneal dissemination in an intraperitoneal xenograft mouse model which were consistent with our findings (Figure 3C) [14].